The components of net pension expense for the three and sixnine month periods ended JuneSeptember 30, 2008 and 2007, for our U.S. andnon-U.S. defined benefit retirement plans are as follows (in millions):

The components of net periodic benefit expense for the three and sixnine month periods ended JuneSeptember 30, 2008 and 2007, for our U.S. and Puerto Rico postretirement benefit plans are as follows (in millions):

We contributed approximately $18$33 million during the sixnine month period ended JuneSeptember 30, 2008 to our U.S. and Puerto Rico defined benefit plans and may makedo not anticipate making additional contributions of up to $6 million duringfor the remainder of 2008. We contributed $6approximately $9 million to our foreign-based defined benefit plans in the sixnine month period ended JuneSeptember 30, 2008 and expect to contribute an additional $5$3 million to these foreign-basedforeign- based plans during the remainder of 2008. Contributions for the U.S. and Puerto Rico postretirement benefit plans are not expected to be significant.

The following is a reconciliation of weighted average shares for the basic and diluted shares computations (in millions):

In the three month period ended JuneSeptember 30, 2008, we repurchased approximately 6.90.7 million shares of our common stock at an average price of $71.55$67.50 per share for a total cash outlay of $495.9$48.6 million, including commissions. In the sixnine month period ended JuneSeptember 30, 2008, we repurchased approximately 8.89.6 million shares of our common stock at an average price of $72.64$72.25 per share for a total cash outlay of $640.2$688.9 million, including commissions. In April 2008, we announced that our Board of Directors authorized a $1.25 billion share repurchase program which expires December 31, 2009. Approximately $1.23$1.18 billion remains authorized under this plan.

We design, develop, manufacture and market reconstructive orthopaedic implants, including joint and dental, spinal implants, trauma products and related orthopaedic surgical products which include surgical supplies and instruments designed to aid in orthopaedic surgical procedures and post-operation rehabilitation. We also provide other healthcare related services. Revenue related to these other healthcare related services currently represents less than 1 percent of our total net sales. We manage operations through three major geographic segments — the Americas, which is comprised principally of the United States and includes other North, Central and South American markets; Europe, which is comprised principally of Europe and includes the Middle East and Africa; and Asia Pacific, which is comprised primarily of Japan and includes other Asian and Pacific markets. This structure is the basis for our reportable segment information discussed below. Management evaluates operating segment performance based upon segment operating profit exclusive of operating expenses pertaining to global operations and corporate expenses, share-based compensation, certain claims, settlement expense, acquisition, integration and other expenses, inventorystep-up, in-process research and development write-offs and intangible asset amortization expense. Global operations include research, development engineering, medical education, brand management, corporate legal, finance, and human resource functions, and U.S. and Puerto Rico based manufacturing operations and logistics. Intercompany transactions have been eliminated from segment operating profit. Net sales and segment operating profit are as follows (in millions):

In November 2007, we received a civil investigative demand from the Massachusetts Attorney General’s office seeking additional information regarding the financial relationships we publicly disclosed pursuant to the DPA with a number of Massachusetts healthcare providers. We received a similar inquiry from the Oregon Attorney General’s office in October 2008. We are cooperating fully with the investigators with regard to this matter. We understand that similar inquiries were directed to other companies in the orthopaedics industry.these matters.

In September 2007, the Staff of the SEC informed us that it was conducting an informal investigation regarding potential violations of the Foreign Corrupt Practices Act in the sale of medical devices in a number of foreign countries by companies in the medical device industry. We understand that at least four other medical device companies received similar letters. We are fully cooperating with the SEC and the U.S. Department of Justice with regard to this informal investigation.

Following announcement of our entry into the DPA and CIA and commencement of the informal SEC investigation described above, two shareholder derivative actions were filed in Kosciusko Superior Court in Warsaw, Indiana. The first action, captioned Bottner v. Dvorak et al., was filed on October 16, 2007. The second action, captioned Capizzi v. Dvorak et al., was filed on October 30, 2007. On November 19, 2007, these two cases were consolidated under the caption In re Zimmer, Inc. Derivative Litigation. The plaintiffs seeksought to maintain the action purportedly on our behalf against sixfive of our current directors and twothree former directors. On December 10, 2007, the plaintiffs filed a consolidated amended derivative complaint, which alleges,alleged, among other things, breaches of fiduciary duty by the individual defendants which allegedly allowed misconduct to occur, including alleged